HomeCompareDCT vs PFE

DCT vs PFE: Dividend Comparison 2026

DCT yields 26.80% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $26.4K in total portfolio value· pulled ahead in Year 9
10 years
DCT
DCT
● Live price
26.80%
Share price
$18.99
Annual div
$5.09
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$3.28
Full DCT calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DCT vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCTPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCT + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCT pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCT
Annual income on $10K today (after 15% tax)
$2,278.30/yr
After 10yr DRIP, annual income (after tax)
$2.79/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,126.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCT + PFE for your $10,000?

DCT: 50%PFE: 50%
100% PFE50/50100% DCT
Portfolio after 10yr
$37.9K
Annual income
$13,606.91/yr
Blended yield
35.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DCT
Analyst Ratings
1
Buy
10
Hold
1
Sell
Consensus: Hold
Price Target
$24.00
+26.4% upside vs current
Range: $12.00 — $48.00
Altman Z
15.5
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCT buys
0
PFE buys
0
No recent congressional trades found for DCT or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCTPFE
Forward yield26.80%6.20%
Annual dividend / share$5.09$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$24.7K$51.1K
Annual income after 10y$3.28$27,210.54
Total dividends collected$2.9K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$24.00$27.50

Year-by-year: DCT vs PFE ($10,000, DRIP)

YearDCT PortfolioDCT Income/yrPFE PortfolioPFE Income/yrGap
1$12,040$1,340.18$9,161$701.38+$2.9KDCT
2$13,637$754.02$8,610$859.79+$5.0KDCT
3$14,991$399.07$8,366$1,081.25+$6.6KDCT
4$16,245$204.99$8,483$1,405.66+$7.8KDCT
5$17,486$103.81$9,084$1,907.24+$8.4KDCT
6$18,762$52.21$10,418$2,732.78+$8.3KDCT
7$20,102$26.18$13,007$4,193.56+$7.1KDCT
8$21,522$13.11$18,010$7,005.87+$3.5KDCT
9← crossover$23,035$6.56$28,216$12,979.89$5.2KPFE
10$24,651$3.28$51,081$27,210.54$26.4KPFE

DCT vs PFE: Complete Analysis 2026

DCTStock

Duck Creek Technologies, Inc. provides software-as-a-service core systems to the property and casualty insurance industry in the United States and internationally. The company provides Duck Creek Policy, a solution that enables insurers to develop and launch new insurance products and manage various aspects of policy administration ranging from product definition to quoting, binding, and servicing; Duck Creek Billing that provides payment and invoicing capabilities, such as billing and collections, commission processing, disbursement management, and general ledger capabilities for insurance lines and bill types; and Duck Creek Claims that supports entire claims lifecycle from first notice of loss through investigation, payments, negotiations, reporting, and closure. It also offers Duck Creek Rating that allows carriers to develop new rates and models and deliver quotes in real-time based on the complex rating algorithms; Duck Creek Insights, an insurance analytics solution that allows carriers to gather and analyze data from internal and external sources and facilitate analysis and reporting on a single system; Duck Creek Digital Engagement that offer digital interactions between property and casualty insurers and their agents, brokers, and policyholders; and Duck Creek Distribution Management that automates sales channel activities for agents and brokers, including producer onboarding, compliance, and compensation management. In addition, the company provides Duck Creek Reinsurance Management that automates financial and administrative functions; and Duck Creek Industry Content that provides pre-built content, including base business rules, product designs, rating algorithms, data capture screens, and workflows for insurance lines of business, such as commercial auto, inland marine, and workers compensation. It has a partnership with Shift Technologies, Inc. to implement AI fraud detection. The company was founded in 2016 and is based in Boston, Massachusetts.

Full DCT Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DCT vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCT vs SCHDDCT vs JEPIDCT vs ODCT vs KODCT vs MAINDCT vs JNJDCT vs MRKDCT vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.